Biotech | May 06, 2022
Procter & Gamble Health posts 14 per cent growth in net profit in Q3
The increase in PAT is driven by higher sales and lower marketing and depreciation charge vs the same period last year
The increase in PAT is driven by higher sales and lower marketing and depreciation charge vs the same period last year
Company will expand the existing production site in Wuxi to significantly increase biopharma single-use assemblies and custom design capabilities
Infigratinib is not FDA-, Health Canada- or Therapeutics Goods Association-approved for any other indication
He will be leading the business, operations, P&L, and growth strategy for StanPlus
Onshore manufacturing facility is expected to be based in Quebec and produce up to 100 million mRNA respiratory vaccine doses annually
South Carolina’s largest health system adopts Philips software solutions for patient monitoring and enterprise imaging, helping to drive interoperability and data analytics, and deliver on Quadruple Aim
Approval based on groundbreaking Phase 3 EXPLORER-HCM trial demonstrating benefit in patients receiving Camzyos versus placebo
It is expanding the diagnostics business footprint in North East India
Danish National Genome Center partners with Lifebit to deliver nationwide personalised medicine
Business EPS of €1.94, up 20.5% on a reported basis and 16.1% at CER, also benefitting from an improved effective tax rate
Subscribe To Our Newsletter & Stay Updated
